Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?


Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.

Aim(s): To investigate the exploratory use of radiomic analysis of 68Ga-DOTATOC PET/CT as a predictive tool for PRRT response in two patients with a different outcome.

Materials and methods: We retrospectively analyzed PET data from 2 patients (pt) with rectum (A) and pancreatic (B) G2 NET respectively treated by surgery and somatostatin analogue, chemotherapy and everolimus for liver metastasis and 6 cycles of 177Lu-DOTATOC for disease progression. PRRT response was assessed according to RECIST 1.1 criteria. PET parameters and radiomic features (RFs) were compared among the pt with the Wilcoxon Mann Whitney test. Furthermore, variation in RFs between PET scan was compared with the Kruskal Wallis test.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liberini V

Authors: Liberini V, Rampado O, Gallio E, De Santi B, Ceci F,

Keywords: radiomic, PRRT, NET, SSTR-RADS, NETPET grade, RECIST 1.1 criteria, 68Ga-DOTATOC PET/CT, tumor/spleen ratio, radiomic analysis of 68Ga-DOTATOC PET/CT, radiomic features,

To read the full abstract, please log into your ENETS Member account.